Zofenopril is a medication that protects the heart and helps reduce high blood pressure. It is an angiotensin-converting enzyme inhibitor. Chemically it is administered as an oral prodrug that is hydrolyzed in vivo to the active sulfhydryl-containing metabolite zofenoprilat, which binds to and inhibits ACE, reducing angiotensin II formation and decreasing vasoconstriction and aldosterone-mediated sodium retention; zofenopril exhibits high tissue affinity for the cardiovascular system, is characterized by good oral bioavailability, and is cleared by combined renal and hepatic pathways, making it suitable for chronic management of hypertension and for improving outcomes in certain patients with ischemic heart disease when used according to clinical guidance.
Typical quality control specifications for zofenopril active pharmaceutical ingredient and formulated material monitor related substances and degradation products, including the active metabolite zofenoprilat, desalkyl derivatives, oxidation products of the sulfur moiety such as sulfoxide and sulfone, epimeric or stereoisomeric impurities, ester hydrolysis products and small-molecule cleavage products, plus usual residual solvents and water; typical specification ranges applied during batch release testing are that individual identified related substances are controlled in the range of up to 0.1 to 0.5 percent by weight depending on identification and toxicological assessment, oxidation products such as sulfoxide and sulfone are often limited to about 0.1 to 0.2 percent each, and total impurities are commonly limited to no more than about 1.0 percent, with residual solvents and heavy metals controlled to pharmacopeial limits and water content specified to ensure stability.
Zofenopril is used to treat high blood pressure and to provide cardioprotective benefits in selected patients with ischemic heart conditions; it is prescribed to reduce systemic vascular resistance and cardiac afterload and, when indicated by a clinician, to improve clinical outcomes in heart disease management.
Common side effects include cough, dizziness, headache, fatigue and gastrointestinal disturbances; less common but potentially serious effects include angioedema, hypotension, hyperkalemia and renal function changes, so monitoring of blood pressure, renal function and electrolytes is recommended during therapy.
Zofenopril is converted in the body to zofenoprilat, which inhibits the angiotensin-converting enzyme and thereby prevents conversion of angiotensin I to angiotensin II, leading to vasodilation, reduced aldosterone secretion, lowered sodium and water retention and a reduction in blood pressure and cardiac workload.
